Johan Neyts is full professor of virology at the University of Leuven, Belgium. He teaches virology at the medical school and at the school of dentistry. His lab is deeply involved in the development of antivirals against SARS-CoV-2. A second focus of the lab is the development of novel vaccine technologies. To that end, the yellow fever vaccine is being used as a vector. Using this technology, his team has developed a potent single-shot SARS-CoV-2 vaccine candidate. Johan Neyts is a past president of the International Society for Antiviral Research (www.isar-icar.com). Four classes of antivirals discovered in his laboratory have been licensed to major pharmaceutical companies (two for HCV, one for dengue and one for rhino/enteroviruses). He has published more than 500 papers in peer reviewed journals and has given around 230 invited lectures. He is regularly interviewed by the media.